The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

MGUS (Monoclonal Gammopathy of Undetermined Significance)

Premalignant plasma cell disorder with risk of progression to multiple myeloma

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is MGUS (Monoclonal Gammopathy of Undetermined Significance)?

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition defined by detection of a monoclonal protein on serum protein electrophoresis, fewer than 10 percent plasma cells in the bone marrow, and absence of end-organ damage. It is found in roughly 3 to 4 percent of individuals over age 50.

MGUS is divided into three types: non-IgM MGUS (most common, around 70 percent), IgM MGUS (about 15 percent), and light-chain MGUS (about 15 percent). Non-IgM MGUS can progress to multiple myeloma, and IgM MGUS can progress to Waldenstrom macroglobulinemia. Annual progression risk is approximately 1 percent, and lifetime cumulative risk is meaningful.

Risk stratification uses M-protein level, M-protein type, and free light-chain ratio. Patients with low-risk MGUS (none of the three risk factors) have a 20-year progression risk of about 5 percent, while those with high-risk MGUS (all three factors) have a 20-year risk of about 58 percent. There is no indication for treatment; structured surveillance is the standard.

Symptoms

Usually asymptomatic and found incidentally
Monoclonal band on protein electrophoresis
Bone pain if progression to myeloma occurs
Renal dysfunction with progression
Anemia and fatigue with progression

Risk Factors

Older age (over 50)
Male sex
Black ancestry (2 to 3-fold higher prevalence)
Family history of plasma cell disease

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Monoclonal band detected on protein electrophoresis
  • Rising M-protein level on follow-up
  • New bone pain, anemia, or kidney problems

Treatment Methods

01
No treatment is indicated; surveillance is the standard
02
Low-risk: laboratory follow-up every 6 months
03
Intermediate to high-risk: laboratory follow-up every 3 to 6 months
04
Track serum M-protein, free light chains, and complete blood count
05
Bone marrow biopsy when indicated
06
Patient education on signs of progression

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.